At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 64 enrolled
Drug / intervention
RDEA3170 15 mg +5 moredrug
Likely dose
RDEA3170 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Randomized, Open-Label Study to Evaluate the Pharmacodynamic Effects and Safety of RDEA3170 Administered in Combination With Febuxostat Compared to Febuxostat Administered Alone in Adult Subjects With Gout
In Brief
A Phase 2 clinical trial evaluating RDEA3170 15 mg, RDEA3170 10 mg, and 4 other interventions for Gout. Completed, enrolled 64 participants across 6 sites.
Detailed Summary
This is a Phase 2a, randomized, open-label, multicenter study to assess the pharmacodynamic (PD) effects and safety of RDEA3170 administered in combination with febuxostat compared to febuxostat administered alone in adult subjects with gout.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGout
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartOct 2014
Primary CompletionJul 2015
Study CompletionFeb 2016
TodayJul 2026
First PostedSep 23, 2014
Enrollment StartOct 1, 2014
Primary CompletionJul 1, 2015
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 11.8 years ago
Interventions
RDEA3170 15 mgdrug
RDEA3170 10 mgdrug
RDEA3170 2.5drug
RDEA3170 5 mgdrug
Febuxostat 40 mgdrug
Febuxostat 80 mgdrug